Compare Johnson & Johnson (JNJ) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Atlassian Corporation PLC — how do they compare? Johnson & Johnson trades at $260.45 (market cap $626.09B), while Atlassian Corporation PLC trades at $152.62 (market cap $39.10B). The key difference: Johnson & Johnson is far larger — about 16× Atlassian Corporation PLC's market cap, and Johnson & Johnson pays a 2.06% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| JNJ | TEAM | |
|---|---|---|
Market Cap | $626.09B | $39.10B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $182.36 |
52-Week Low | $172.78 | $57.15 |
Enterprise Value | $654.37B | $39.09B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Atlassian (TEAM) trades at $152.49, up 0.41% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported strong Q4 2026 earnings, beating estimates with 28% revenue growth and achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a consensus price target of $161.93.
The outlook is favorable given accelerating cloud revenue and AI platform adoption, though risks include high valuation multiples and potential growth deceleration. Net losses have narrowed significantly, but the stock's EV/EBITDA of 184.26 suggests premium pricing. Continued execution on enterprise deals and margin expansion are key for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
